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Objective: To assess the prevalence of polycystic ovary syndrome (PCOS) in a cohort of young women with pre-
vious idiopathic central precocious puberty (ICPP) at least 3 years after menarche, and to look for any predictive
factors of PCOS at the time ICPP was diagnosed.
Design: Longitudinal study.
Setting: Pediatrics unit, Verona, Italy.
Patient(s): Forty-six young women (18.1  3.0 years) who had been treated with GnRH analogues during child-
hood, observed at gynecologic age of 6.23  3.3 years.
Intervention(s): Semistructured interview concerning cycles, physical exam, blood sampling, and transabdominal
pelvic ultrasound.
Main Outcome Measure(s): Oligomenorrhea, LH, FSH, E2, T, DHEAS, free T, delta4-androstenedione, 17-OHP,
P, polycystic ovary morphology (PCOM).
Result(s): Fifteen percent of the young women had oligomenorrhea, 28% clinical hyperandrogenism, 48% bio-
chemical hyperandrogenism, and 37% PCOM.A total of 32% of the patients had PCOS according to the Rotterdam
definition and 30% had PCOS according to the Androgen Exess Society. The prevalent phenotype of PCOS was
characterized by clinical and/or biochemical hyperandrogenism and PCOM.We did not find any predictive factors
for PCOS at the time ICPP was diagnosed.
Conclusion(s): Patients with ICCP are prone to developing PCOS. The prominent phenotype in this cohort was
PCOM associated with clinical and/or biochemical hyperandrogenism. Further follow-ups of these young adult
patients will clarify whether this phenotype persists and if it will have important long-term implications regard-
ing increased risk of infertility or metabolic complications. (Fertil Steril 2010;93:1185–91. 2010 by Ameri-
can Society for Reproductive Medicine.)
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hyperandrogenismPolycystic ovary syndrome (PCOS) is the leading cause of
anovulation, hirsutism and infertility; PCOS occurs in
5%–10% of reproductive age women (1, 2). Adolescent girls
with PCOS, similar to adult women with the condition, are at
increased risk for development of type 2 diabetes mellitus
and the metabolic syndrome (3). It is important to recognize
girls and young women at risk for PCOS, because early inter-
vention may prevent long-term sequelae and improve quality
of life (4).
There has been little agreement on the criteria used to di-
agnose PCOS. In 2003, a consensus conference in Rotterdam,
based on majority opinion rather than clinical trial evidence,
proposed new criteria for the diagnosis of PCOS that included
more phenotypes of PCOS and recognized that women withJuly 19, 2008; revised October 28, 2008; accepted November
; published online January 9, 2009.
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polycystic ovaries could have the syndrome (5). Several
researchers have argued that such criteria may be nonspecific
(6, 7), and in 2006 the Androgen Excess Society (AES) Task
Force on Phenotype of PCOS narrowed the Rotterdam crite-
ria to exclude women who did not have androgen excess (8).
Some authors considered these criteria to be the most useful
for diagnosis of PCOS in adolescence (9).
No single factor accounts for the spectrum of abnormali-
ties noted in PCOS, which is thought to be a complex disor-
der. Current data suggest that impaired hypothalamic
sensitivity to progesterone feedback mediated by hyperan-
drogenism is a potential etiology of the LH hypersecretion
observed among women with PCOS (10). Several lines of
evidence suggest the role of primary hypothalamic defect
in PCOS, involving pituitary hypersensitivity to GnRH and
a disorder of diurnal secretion or exaggerated pulsatile
release of LH (11).
Idiopathic central precocious puberty (ICPP) resembles
PCOS in that it is characterized by increased LH levels and
pulse frequency (12–14). Case observations have prompted
speculation that an underlying neuroendocrine dysfunctionFertility and Sterility Vol. 93, No. 4, March 1, 2010 1185
ociety for Reproductive Medicine, Published by Elsevier Inc.
manifests first as ICPP and later as PCOS (15). PCOS oc-
curred in 10% of one European series of ICPP (16), but it
was not found in two others (17, 18). Thus, it is unclear
whether the association of PCOS with ICPP is any more fre-
quent than would be expected by chance (1), and it would be
important to know whether women with ICCP are prone to
develop PCOS, thereby requiring adequate follow-up after
menarche.
The aims of the present study were: 1) to find the preva-
lence of PCOS in a cohort of young women who had
ICCP; and 2) to detect any predictive factors of PCOS at
the time ICPP was diagnosed.MATERIALS AND METHODS
Subjects
Among the 170 patients treated for ICPP from 1990 to 2002
at the Pediatric Division of the Verona Hospital, 46 patients
fulfilled the following criteria:
1) Their ICPP was diagnosed according to the classic def-
inition (19): a) onset of breast development (stage B2 or
above according to Tanner) before 8 years of chrono-
logic age (CA); b) pubertal LH response (more than 7
IU/L) to GnRH stimulation test; c) increment of height
velocity and advancement of bone age (BA) by at least
1 year over CA; d) uterine length >3.5 cm and ovarian
volumes>1.5 cm3 at ultrasound. No evidence of hypo-
thalamic-pituitary organic lesions at magnetic reso-
nance imaging (MRI) allowed the ‘‘idiopathic’’
classification. None of the patients had an adrenal or
clinical manifestation of McCune-Albright syndrome
or other causes of precocious puberty.
2) They had a postmenarche age ofR3 years at the time
of the study, and none were taking hormones or had
other causes of ovary dysfunction.Methods
The study protocol was in accordance with the Helsinki II
declaration, and informed consent was obtained from the pa-
tients and/or the parents before each subject was enrolled in
the study.
All 46 young women were studied during the early follic-
ular phase of their menstrual cycle, i.e., during days 2–8.
All the subjects had a semistructured interview with an ex-
pert clinician concerning their cycles (e.g., interval times, du-
ration of flow, and associated symptoms) and fertility history.
To determine menstrual cycle lengths, they kept a diary for
a 3-month period. The frequency of menstrual bleeding was
classified as regular (menses every 25–35 days) or oligome-
norrheal (menses>35 days for at least 3 consecutivemonths).
We use the term menarche here to refer to the first menstrual
period after discontinuation of GnRH agonist treatment.
All of the subjects underwent a clinical examination, and
height, weight, pubertal stage, and signs of clinical hyperan-1186 Franceschi et al. PCOS and ICPPdrogenism were noted. Target height (TH) was calculated as
midparental height adjusted for gender (6.5) (20). Predicted
adult heights (PAH) were calculated according to Bayley and
Pinneau’s method (21). Body mass index (BMI) was calcu-
lated as weight (kg) divided by height squared (m2) and
was expressed in standard deviation score (SDS) for CA
(22). A woman was considered to be overweight at the time
of the study if her BMI fell between 25 and 30, and obese
if her BMI was >30. Puberty development was clinically
assessed by Marshall and Tanner standards (23). Clinical
hyperandrogenism was evaluated using modified Ferriman-
Gallwey (mFG) scores (24). Acne was considered depending
on its clinical aspect.
On the same day, patients underwent blood tests for fasting
insulin, glucose, lipids, basal gonadotropins (LH, FSH), E2,
T, DHEAS, free T, delta4-androstenedione (A), 17-hydroxy-
progesterone (17-OHP), and progesterone (P).
The LH, FSH, A, PRL, E2, DHEAS, insulin, TSH, free T4,
P, and Twere measured by immunochemiluminescence (Im-
mulite 2000 Analyzer; Euro/DPC, Llamberis, Gwynedd,
U.K.). The sensitivities were 0.05 mIU/mL for LH, 0.1
mUI/mL for FSH, 0.3 ng/mL (1.0 nmol/L) for PRL, 0.16
ng/mL (3.4 mIU/L) for A, 15 pg/mL (55 pmol/L) for E2, 3
mg/dL (0.08 mmol/L) for DHEAS, 2 mIU/mL for insulin,
0.004 mIU/mL for TSH, 0.3 ng/dL for free T4, 0.1 ng/mL
(0.3 nmol/L) for P, and 15 ng/dL (0.5 nmol/L) for T. Free T
and 17-OHP were measured by RIA (free T: Adaltis, Bolo-
gna, Italy; 17-OHP: Diagnostic Systems Laboratories, Web-
ster, TX), and the sensitivity was 0.18 ng/mL for free T and
0.01 ng/mL for 17-OHP.
Values of 0.1 IU/L (for LH and FSH), 73.4 pmol/L (for E2)
and 0.63 (for P) were assigned to samples below the detection
limit. All samples were stored at 20C until they were
assayed.
The homeostasis model assessment (HOMA) was used to
estimate insulin resistance (IR) and when HOMA IR was
R2.5, an oral glucose tolerance test was done, and fasting
insulin R15 mcU/mL and/or a peak R150 mcU/mL was
considered to be hyperinsulinemia (25).
A transabdominal uterine and ovarian scan was done using
an ultrasound scanner (GE Logiq 3) with the use of a 3.5 Mhz
convex transducer (GE Medical Siemens, Phoenix, AZ)
when the participants had a full bladder, obtained by volun-
tary urine retention and oral administration of fluids. All the
tests were carried out by the same ultrasonographer, and mul-
tiple images were recorded for each ovary. Uterine and ovar-
ian volume, endometrial thickness, and number, diameter,
and distribution of the follicles were recorded. The measure-
ments for each ovary were taken separately, because there
were variations between the volume and follicle diameter
in each ovary. Ovarian and uterine volumes were calculated
using the ellipsoid formula, calculated as length  width 
height in cm multiplied by 0.5233 (26, 27). The echogenicity
of ovarian stroma was scored subjectively as 0 (normal), 1
(moderately increased), or 2 (markedly increased).Vol. 93, No. 4, March 1, 2010
Exclusion of 21-hydroxylase–deficient nonclassic adrenal
hyperplasia was done using the basal morning 17-OHP level,
with a cut-off value of 2 ng/mL.
Polycystic ovary syndrome was defined according to the
revised 2003 Rotterdam criteria (two out of three) and exclu-
sion of other etiologies (congenital adrenal hyperplasias,
androgen-secreting tumours, Cushing syndrome):
1) Oligo- and/or anovulation;
2) Clinical and/or biochemical signs of hyperandrogen-
ism;
3) Polycystic ovaries at the ultrasound scan.
Polycystic ovary syndrome was also defined according to
the 2006 AES criteria (three of three):
1) Hyperandrogenism: hirsutism and/or hyperandrogene-
mia;
2) Ovarian dysfunction: oligoanovulation and/or polycys-
tic ovaries;
3) Exclusion of other androgen excess or related disor-
ders.
We considered the condition to be oligomenorrhea if men-
ses were>35 days for at least 3 consecutive months and clin-
ical hyperandrogenism if an mFG score was>9 (e.g., greater
than the 95% confidence limit for a control population with
regular menses and documented ovulation [23]) and/or mod-
erate acne was present.
Biochemical hyperandrogenism (hyperandrogenemia)
was defined as an androgen level greater than the 95% confi-
dence limits in previously reported ovulatory control subjects
(24), free T>12.5 pmol/L, DHEAS>400 ug/dL (11.6 mmol/
L), or A >3.5 ng/mL (13.3 nmol/L) or total T >0.80 ng/mL
(2.8 nmol/L). In our institution we confirmed the normal
range for androgens, reported in literature for an adult popu-
lation, on a control group of 20 young women attending the
medical school (age range 21–25 years) in the early follicular
phase of the cycle, using the same assay.
Polycystic ovarianmorphology (PCOM)was defined asR1
ovarywithR12 follicles 2–10mmindiameter in a single plane
and/or an ovarianvolume>10mL in the absence of a dominant
follicle >10 mm, a corpus luteum, or a cyst (1, 28, 29).
We excluded multifollicular ovary morphology, defined as
6–10 follicles 4–10mm in diameter in themaximumplane in ir-
regular distribution without increased ovarian stroma (30, 31).
We did not consider doing transvaginal ultrasound in our pa-
tients, because we visualized the uterine structure and both ova-
ries by transabdominal ultrasound in 100% of cases. Consensus
was reached on the reading of all ultrasounds by the reviewers.
We tested the following data collected at diagnosis as vari-
ables that could be predictive or were associated with PCO or
PCOS, because we wanted to test whether an earlier activa-
tion of the adrenals or of the pituitary-gonadal axis could re-
sult in an increased prevalence of PCOS and PCOM: age at
diagnosis, age at telarche, age at pubarche, BA, LH-FSH-
E2 baseline and peaks, A, and 17-OHP. Furthermore, BMIFertility and SterilitySDS was tested at diagnosis, because it could determine
increased BMI in adults, insulin resistance, and increased
prevalence of PCOS and PCOM.
At the time of the study, we tested length of treatment with
GnRH agonist and CA at menarche, to check if a longer sup-
pression of the pituitary-gonadal axis and/or a later menar-
cheal age could protect from PCOM or PCOS. Furthermore,
we tested GA, length of cycles, mFG score; LH-FSH-E2, A,
free T, total T, 17-OHP, mean right-left ovarian volumes,
and number of follicles to find correlations and differences be-
tween groups regarding hyperandrogenism parameters. The
BMI SDS, HOMA IR, and lipids were checked, because
some authors have reported that in girls with PCOS the
body fractions of fat and abdominal fat are high, even in the
absence of obesity.
We did not test predicted and target heights, or height SDS
at diagnosis and at the time of the study. These parameters are
here reported only to show that our patients with ICPP,
treated with GnRH agonist, reached the final height.Statistical Analysis
Results are expressed as mean  SD. Statistical analysis was
performed with SPSS version 14.0 (SPSS, Chicago, IL). Data
that were not normally distributed were log normalized for
comparison. Statistical analysis of the results was assessed
using the Student t test, paired and unpaired if required. Cor-
relations between two parameters were determined by Pear-
son correlation coefficient analysis. The Student t test was
used to compare groups and variables. A P value of < .05
was considered to be significant.RESULTS
The clinical and auxologic data of the patients when diag-
nosed with ICCP and at the time of the study are reported in
Table 1; biochemical and ultrasound data at the time of the
study are reported in Table 2. None of the subjects were small
for gestational age. Two young women had familial histories
of polycystic ovaries but none of insulin resistance.At the time
of the study, five patients (11%) were overweight and two
(4%) were obese. The BMI SDS in the total study population
was not statistically different from the BMI SDS for CA and
for BA at start of treatment (P¼.11 and P¼.73, respectively).
Six patients (13%) had HOMA IR >2.5, but an oral glucose
tolerance test (OGTT) did not show insulin resistance. The
HOMA IR was related to BMI (P<.001; r ¼ 0.55). At the
time of the study, none of the patients had ever been pregnant.
Figure 1 shows the prevalence of Rotterdam criteria in this
cohort of patients. Fifteen percent of the women (7 out of 46)
had oligomenorrhea, and at the time of being diagnosed with
ICPP they did not differ in age at telarche and pubarche or in
biochemical data with the girls who had normal cycles.
Clinical hyperandrogenism was found in 28% of the
patients (13 out of 46), and hirsutism was the most common
feature (10 patients).1187
TABLE 1
Clinical and auxologic data of the patients
(mean ± SD).
Patient data
At diagnosis of ICPP
Age at diagnosis (y) 7.65  0.20
Age at telarche (y) 7.32  0.50
Age at pubarche (y) 7.91  0.80
BA at diagnosis (y) 10.15  1.90
Height (cm) 137.0  11.0
Height SDS for CA 0.97  1.10
Height SDS for BA 0.48  0.70
TH (cm) 160.0  5.0
PAH (cm) 158.0  10.0
BMI SDS for CA 0.64  0.82
BMI SDS for BA 0.28  0.82
At time of the study
Length of treatment
with GnRH agonist (y)
2.81  1.70
CA (y) 18.1  3.00
CA at menarche (y) 12.22  0.93
GA (y) 6.23  3.30
Height (cm) 160.0  6.0
Height SDS for CA 0.33  1.10
BMI (kg/m2) 22.21  3.94
BMI SDS CA 0.14  1.10
Ferriman-Gallwey score 9.12  4.14
Note: BA ¼ bone age; CA ¼ chronologic age; GA ¼ gy-
necologic age; ICPP ¼ idiopathic central precocious
puberty; PAH ¼ predicted adult height; SDS ¼ stan-
dard deviation score; TH ¼ target height.
Franceschi. PCOS and ICPP. Fertil Steril 2010.
TABLE 2
Hormonal and ultrasound findings in all 46
patients (mean ± SD).
Patient data
At diagnosis of ICPP
LH baseline (mU/mL) 1.90  1.85
FSH baseline (mU/mL) 6.57  13.67
LH peak (mU/mL) 23.43  18.78
FSH peak (mU/mL) 16.21  9.29
LH/FSH ratio 1.67  1.09
E2 baseline (pg/mL) 28.94  13.76
E2 peak (pg/mL) 32.91  24.50
A (ng/mL) 1.20  0.47
17-OHP baseline (ng/mL) 1.17  0.88
At time of study
LH (mU/mL) 6.10  3.10
FSH (mU/mL) 7.51  1.90
E2 (pg/mL) 53.95  41.50
P (ng/mL) 0.54  0.40
DHEAS (mg/dL) 209.80  87.40
A (ng/mL) 3.50  1.10
Free T (pmol/L) 7.79  1.90
Total T (ng/mL) 0.46  0.10
17-OHP (ng/mL) 1.30  0.40
HOMA IR 1.78  1.00
Mean ovarian volume (mL) 7.50  3.00
Right ovary volume (mL) 7.24  3.22
Left ovary volume (mL) 7.30  3.45
No. of follicles 12.35  3.19
Note: Data are reported as mean SD. To convert to SI
units, multiply E2 by 3.671 (result in pmol/L); P by 3.18
(result in nmoL/L), DHEAS by 0.02714 (result in mmol/
L), A by 3.4916 (result in nmoL/L), total T by 0.035
(result in nmoL/L), and 17-OHP by 3.03 (result in
nmol/L). HOMA IR¼ homeostasis model assessment
insulin resistance.
Franceschi. PCOS and ICPP. Fertil Steril 2010.Biochemical hyperandrogenism was found in 48% (22 out
of the 46): All of these patients had high A, associated in two
subjects with high DHEAS. Delta4-androstenedione in this
cohort (3.50 1.10 ng/mL) was the androgen that was signif-
icantly raised compared with values of the control group of
20 young women previously tested (2.47  0.84 ng/mL;
P¼.008). The A levels were related to 17-OHP (P¼.012;
r ¼ 0.38) and DHEAS (P¼.002; r ¼ 0.46), but not to ovary
volume, number of follicles, or LH and FSH levels. At the
time of the study, LH levels were only slightly high in two pa-
tients, and the LH/FSH ratio was >2 in two other patients,
none of whom had hyperandrogenism.
Twenty-three out of 46 patients (50%) showed multifollic-
ular ovaries. PCOM was found by ultrasound in 17 out of 46
patients (37%), and six patients (13%) had normal ovary mor-
phology. Mean ovarian volume in the 46 women correlated
with free T (P¼.008; r ¼ 0.65).
According to the Rotterdam criteria, 15 out of 46 patients
(32%) had PCOS, and Figure 2 shows the prevalence of the
different PCOS phenotypes: One patient had oligomenorrhea1188 Franceschi et al. PCOS and ICPPwith clinical and/or biochemical hyperandrogenism and
PCOM; four had oligomenorrhea and clinical and/or bio-
chemical evidence of hyperandrogenism; one had oligome-
norrhea and PCOM; and nine showed clinical and/or
biochemical hyperandrogenism with PCOM. There were no
statistically significant differences, at the time ICPPwas diag-
nosed, in auxologic and biochemical data (LH and FSHpeaks,
E2, A, and 17-OHP) between PCOS and non-PCOS subjects.
According to the AES criteria, 14 out of 46 patients (30%)
had PCOS.
DISCUSSION
This is the first longitudinal study on the prevalence of PCOS in
a homogeneous sample of46youngwomenpreviously affected
by ICPP, treated with GnRH agonist, and examined more
than 3 years after menarche, at the same phase of the cycle.Vol. 93, No. 4, March 1, 2010
FIGURE 1
Prevalence of Rotterdam criteria in the 46 women at
the time of the study. PCOM ¼ polycystic ovary
morphology.
Franceschi. PCOS and ICPP. Fertil Steril 2010.The prevalence of PCOS in these subjects was 32% using
the Rotterdam 2003 criteria and 30% using the AES criteria.
We found normal menstrual cycle pattern in most patients
with ICPP, and the prominent phenotype of PCOS in this
cohort was clinical and/or biochemical hyperandrogenism
associated with PCOM.
Hyperandrogenism
Regarding clinical hyperandrogenism, the prevalence of hir-
sutism (23%) was similar to that reported by other authors inFIGURE 2
Phenotypes of patients with polycystic ovary syndrome (n
PCOM ¼ polycystic ovary morphology.
Franceschi. PCOS and ICPP. Fertil Steril 2010.
Fertility and Sterilitypatients who had ICPP (14) and higher than the 12% reported
for normal women (32).
Regarding biochemical hyperandrogenism, the 48% prev-
alence in the present patients is higher than levels reported by
other authors in patients who had ICPP (33). In contrast, we
found similar levels of A to Lazar et al. (34) in girls who had
CPP and showed a PCO-like syndrome at 0.5–3.5 years after
menarche with exaggerated adrenal response to ACTH
stimulation.
Excessive secretion of androgens, prominent in the delta4-
pathways in the ovaries, is reported in the literature as func-
tional ovarian hyperandrogenism and is considered to be the
prominent abnormality in women with PCOS (35). There is
scarce information on A and PCOS, and the AES (8) has re-
ported that the usefulness of also measuring this hormone is
unclear, but it may help to increase the number of subjects
identified as hyperandrogenemic by approximately 10%.
Many authors (32, 36) have considered A to be among the an-
drogens that define biochemical hyperandrogenism accord-
ing to the Rotterdam criteria. Hyperandrogenism is the
main feature of PCOS, but the pathophysiologic characteris-
tics of this syndrome are not fully understood. We know that
complex interaction between the action of gonadotropins, the
ovaries, androgens, and insulin is involved (37).
In the present patients, A levels were related to 17-OHP
and DHEAS. We excluded adrenal hyperplasia when ICPP
was diagnosed, through an ACTH test in those who also
had precocious pubarche, and through low basal morning
17-hydroxyprogesterone levels at the time of the study.
Most of the women who had ICPP at the time of this study
did not appear to be obese or insulin resistant. Therefore it
is more likely that overproduction of ovarian androgen was
caused by an early intrinsic abnormality in GnRH pulse gen-
erator pulsation that they showed at puberty. This line of¼ 19). H ¼ hyperandrogenism; O ¼ oligomenorrhea;
1189
thinking is in agreement with other authors (15), but primary
thecal dysfunction, when cells are more efficient at convert-
ing androgenic precursors to A (mediated by cytochrome
p450c17), cannot be excluded.Ovary Morphology
The normal adolescent ovary is known to histologically re-
semble a polycystic ovary, and the perimenarchal combina-
tion of a high number of follicles and mature gonadotropin
stmulation leads to a greater number of large antral follicles
and a slightly greater ovarian size than at any other stage (38).
In our patients who had ICPP, examined at least 3 years af-
ter menarche, the prevalence of multifollicular ovaries was
30%, similar to 25% reported in healthy adolescent volun-
teers using the same criteria (30, 31).
In contrast, 37%of our patients had PCOM. The prevalence
is higher than the 10% prevalence in the general population of
regularly menstruating postmenarchal schoolchildren and
also that in ICPP (10%–24%) in perimenarchal age by other
studies (16, 33, 39), which used different criteria.
According to some authors, PCOM in women with regular
cycles has not been considered a major risk factor for the de-
velopment of PCOS (32), and over time most fail to meet the
criteria for PCOM, probably because of a decrease in volume
and number of antral follicles with aging. In contrast, other
authors reported that PCOM with ovulatory cycles exists as
a discrete entity and represents the mildest form of ovarian
hyperandrogenism (40).
Relationships among ovarian histology, architecture as
perceived by ultrasound, and function are not estabilished,
but PCOM seems to be a marker for excessive thecal andro-
gen production, even if in some patients with PCOM thecal
androgen excess is not manifest as hyperandrogenemia, the
reason for which is not known (38).
The prevalence of PCOS in our subjects was 32% using the
Rotterdam 2003 criteria and 30% using the AES criteria,
higher than the prevalence reported by other authors in pa-
tients who had ICPP (16–18), but older criteria for PCOS
were used in those studies.
Abnormal gonadotropin dynamics with excess ovarian
production of androgens and PCOM may occur despite the
treatment with GnRH agonist in patients who had ICPP. It
would be interesting if later studies could enroll as control
subjects a group of girls with ICPP who had not been treated
with GnRH agonist to evaluate whether GnRH therapy per se
could modify the prevalence of PCOS. What we know from
a randomized study (33) in treated and nontreated girls
with ICPP is only that adverse effects of treatment on the
reproductive function can be excluded.
Unfortunately, we did not find any risk or predictive factors
of PCOM or clinical and/or biochemical hyperandrogenism
at the time ICPP was diagnosed. The birth weight, age at
telarche or pubarche, BMI SDS, or gonadotropin and andro-1190 Franceschi et al. PCOS and ICPPgen levels could not predict the risk of developing PCOM or
PCOS in these women with ICCP.
Nevertheless, we can conclude that patients who had ICCP
are prone to developing PCOS. The prominent phenotype in
the present cohort wasPCOM associated with clinical and/or
biochemical hyperandrogenism. Further follow-ups of these
patients will verify whether this phenotype persists and if it
has important long-term implications regarding increased
risk of infertility or metabolic complications.REFERENCES
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